NO20020983D0 - Metoder og blandinger til administrasjon av terapeutiske midler - Google Patents

Metoder og blandinger til administrasjon av terapeutiske midler

Info

Publication number: NO20020983D0
Authority: NO; Norway
Prior art keywords: methods; cationic; compositions; cells; solubilized
Prior art date: 1999-09-01

Application number

NO20020983A

Other languages

English (en)

Other versions

NO20020983L (no

NO329773B1 (no

Inventor

Kesavan Esuvaranathan

Ratha Mahendran

Carmel Lawrencia

Original Assignee

Genecure Pte Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-01

Filing date

2002-02-27

Publication date

2002-02-27

2002-02-27 Application filed by Genecure Pte Ltd filed Critical Genecure Pte Ltd

2002-02-27 Publication of NO20020983D0 publication Critical patent/NO20020983D0/no

2002-04-24 Publication of NO20020983L publication Critical patent/NO20020983L/no

2010-12-13 Publication of NO329773B1 publication Critical patent/NO329773B1/no

Links

238000000034 method Methods 0.000 title abstract 5
239000000203 mixture Substances 0.000 title abstract 4
239000003814 drug Substances 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 6
102000040430 polynucleotide Human genes 0.000 abstract 4
108091033319 polynucleotide Proteins 0.000 abstract 4
239000002157 polynucleotide Substances 0.000 abstract 4
229920006317 cationic polymer Polymers 0.000 abstract 3
235000012000 cholesterol Nutrition 0.000 abstract 3
239000000412 dendrimer Substances 0.000 abstract 3
229920000736 dendritic polymer Polymers 0.000 abstract 3
239000008177 pharmaceutical agent Substances 0.000 abstract 3
229920000858 Cyclodextrin Polymers 0.000 abstract 2
125000002091 cationic group Chemical group 0.000 abstract 2
YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 abstract 1
206010005003 Bladder cancer Diseases 0.000 abstract 1
102000007644 Colony-Stimulating Factors Human genes 0.000 abstract 1
108010071942 Colony-Stimulating Factors Proteins 0.000 abstract 1
102000014150 Interferons Human genes 0.000 abstract 1
108010050904 Interferons Proteins 0.000 abstract 1
102000015696 Interleukins Human genes 0.000 abstract 1
108010063738 Interleukins Proteins 0.000 abstract 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 abstract 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 abstract 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
-1 cationic lipid Chemical class 0.000 abstract 1
229940079322 interferon Drugs 0.000 abstract 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000001890 transfection Methods 0.000 abstract 1
201000005112 urinary bladder cancer Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Steroid Compounds (AREA)

NO20020983A 1999-09-01 2002-02-27 In vitro fremgangsmate for transfeksjon av et polynukleotid inn i celler, et transfeksjonsmiddel og en farmasoytisk sammensetning. NO329773B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPQ2593A AUPQ259399A0 (en)	1999-09-01	1999-09-01	Therapeutic agents
PCT/SG2000/000130 WO2001015755A2 (en)	1999-09-01	2000-09-01	Methods and compositions for delivery of pharmaceutical agents

Publications (3)

Publication Number	Publication Date
NO20020983D0 true NO20020983D0 (no)	2002-02-27
NO20020983L NO20020983L (no)	2002-04-24
NO329773B1 NO329773B1 (no)	2010-12-13

Family

ID=3816764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20020983A NO329773B1 (no)	1999-09-01	2002-02-27	In vitro fremgangsmate for transfeksjon av et polynukleotid inn i celler, et transfeksjonsmiddel og en farmasoytisk sammensetning.

Country Status (11)

Country	Link
US (2)	US7320963B2 (no)
EP (1)	EP1208218B1 (no)
JP (1)	JP4995388B2 (no)
AT (1)	ATE292187T1 (no)
AU (2)	AUPQ259399A0 (no)
CA (1)	CA2384425C (no)
DE (1)	DE60019134T2 (no)
ES (1)	ES2240157T3 (no)
NO (1)	NO329773B1 (no)
TW (1)	TWI262085B (no)
WO (1)	WO2001015755A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPQ259399A0 (en) *	1999-09-01	1999-09-23	Lustre Investments Pte Ltd	Therapeutic agents
EP1233671A4 (en) *	1999-11-29	2005-11-02	Mirus Corp	COMPOSITIONS AND METHODS OF DISPOSING MEDICAMENTS USING AMPHIPHILIC BINDING MOLECULARS
WO2003038103A1 (en) *	2001-10-29	2003-05-08	Atso Raasmaja	Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US7153905B2 (en) *	2003-03-21	2006-12-26	The General Hospital Corporation	Hyperbranched dendron and methods of synthesis and use thereof
US8545830B2 (en) *	2003-03-24	2013-10-01	University Of Tennessee Research Foundation	Multi-functional polymeric materials and their uses
JP4649571B2 (ja) *	2003-07-16	2011-03-09	英俊有馬	細胞にｒｎａを導入する方法
BRPI0514387B8 (pt)	2004-08-16	2021-05-25	Cellresearch Corp Pte Ltd	método para isolar células-tronco epiteliais ou mesenquimais/progenitoras da membrana amniótica do cordão umbilical, método in vitro para cultivar células-tronco mesenquimais/progenitoras, composição farmacêutica e uso de uma célula-tronco epitelial ou mesenquimal/progenitora
US9346029B2 (en)	2005-06-06	2016-05-24	The University Of British Columbia	Polymer-based serum albumin substitute
US8287854B2 (en)	2005-10-21	2012-10-16	Cellresearch Corporation Pte Ltd	Skin equivalents derived from umbilical cord mesenchymal stem/progenitor cells and umbilical cord epithelial stem/progenitor cells
ITMI20071173A1 (it) *	2007-06-11	2008-12-12	Univ Degli Studi Milano	Polimeri iperramificati a base di ciclodestrine e poli(amidoammine) per il rilascio controllato di farmaci insolubili
BR112012021991A2 (pt)	2010-03-01	2020-09-01	The University Of British Columbia	policlicerol hiperramificado uso de um poliglicerol hipermanificado, método de adiministração de uma força biologicamente ativa a um tecido biológico, composição farmacêutica e método de síntese de um poliglicerol hiperrramificado.
US20120310140A1 (en)	2010-12-01	2012-12-06	Spinal Modulation, Inc.	Directed delivery of agents to neural anatomy
WO2013074526A2 (en)	2011-11-15	2013-05-23	Byocoat Enterprises, Inc.	Antimicrobial compositions and methods of use thereof
US9931418B2 (en)	2012-08-07	2018-04-03	Northeastern University	Compositions for the delivery of RNA and drugs into cells
JP6139029B2 (ja) *	2013-06-21	2017-05-31	ザカトリックユニバーシティオブコリアインダストリー−アカデミックコーオペレイションファウンデーション	薬物送達用還元性または非還元性ポリヌクレオチド高分子及びその製造方法
CA2944181C (en)	2014-03-27	2019-09-17	Salk Institute For Biological Studies	Compositions and methods for treating type 1 and type 2 diabetes and related disorders
KR102015205B1 (ko)	2015-02-27	2019-08-27	더 솔크 인스티튜트 포 바이올로지칼 스터디즈	리프로그래밍 전구체 조성물 및 그의 사용 방법
US11760977B2 (en)	2016-05-25	2023-09-19	Salk Institute For Biological Studies	Compositions and methods for organoid generation and disease modeling
CN106924746B (zh) *	2017-03-03	2020-11-03	中山大学	复合基因载体及其应用
US12377092B2 (en)	2017-12-11	2025-08-05	Fondazione Istituto Firc Di Oncologia Molecolare (Ifom)	Polycomb inhibitors and uses thereof
US20220107320A1 (en)	2019-02-15	2022-04-07	Incelldx, Inc.	Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
CN113181119B (zh) *	2021-05-08	2023-08-29	深圳市第二人民医院(深圳市转化医学研究院)	载药系统及其制备方法、药物组合物
CN113082001B (zh) *	2021-05-25	2023-05-26	中国科学院广州生物医药与健康研究院	一种核酸递送系统及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
WO1994023697A1 (en)	1993-04-22	1994-10-27	Depotech Corporation	Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5614503A (en)	1993-11-12	1997-03-25	Aronex Pharmaceuticals, Inc.	Amphipathic nucleic acid transporter
US5691316A (en)	1994-06-01	1997-11-25	Hybridon, Inc.	Cyclodextrin cellular delivery system for oligonucleotides
US5543152A (en)	1994-06-20	1996-08-06	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5993850A (en)	1994-09-13	1999-11-30	Skyepharma Inc.	Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
EP0833613A1 (en)	1995-05-26	1998-04-08	Somatix Therapy Corporation	Delivery vehicles comprising stable lipid/nucleic acid complexes
US5830878A (en)	1995-06-07	1998-11-03	Megabios Corporation	Cationic lipid: DNA complexes for gene targeting
US5932241A (en)	1995-06-07	1999-08-03	Valentis, Incorporated	Cationic lipid DNA complexes for gene targeting
EP0955999B1 (en)	1996-08-19	2001-12-05	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Novel liposome complexes for increased systemic delivery
WO1998040499A1 (en) *	1997-03-10	1998-09-17	Heather Lynn Davis	Gene delivery to mucosal epithelium for immunization or therapeutic purposes
WO1998044909A1 (en)	1997-04-04	1998-10-15	Valentis Inc.	Improved methods of delivery using cationic lipids and helper lipids
AU7490098A (en) *	1997-05-15	1998-12-08	Genzyme Corporation	Cationic amphiphile formulations
CA2268945A1 (en) *	1997-06-10	1998-04-02	Genzyme Corporation	Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US6391336B1 (en)	1997-09-22	2002-05-21	Royer Biomedical, Inc.	Inorganic-polymer complexes for the controlled release of compounds including medicinals
AU9404398A (en)	1997-09-23	1999-04-12	Megabios Corporation	Methods for preparing lipids/polynucleotide transfection complexes
AUPQ259399A0 (en) *	1999-09-01	1999-09-23	Lustre Investments Pte Ltd	Therapeutic agents
AU3366901A (en) *	1999-12-30	2001-07-16	Novartis Ag	Novel colloid synthetic vectors for gene therapy

1999
- 1999-09-01 AU AUPQ2593A patent/AUPQ259399A0/en not_active Abandoned
2000
- 2000-09-01 WO PCT/SG2000/000130 patent/WO2001015755A2/en not_active Ceased
- 2000-09-01 AU AU73275/00A patent/AU781684B2/en not_active Ceased
- 2000-09-01 EP EP00961303A patent/EP1208218B1/en not_active Expired - Lifetime
- 2000-09-01 JP JP2001520166A patent/JP4995388B2/ja not_active Expired - Fee Related
- 2000-09-01 ES ES00961303T patent/ES2240157T3/es not_active Expired - Lifetime
- 2000-09-01 CA CA2384425A patent/CA2384425C/en not_active Expired - Fee Related
- 2000-09-01 AT AT00961303T patent/ATE292187T1/de active
- 2000-09-01 DE DE60019134T patent/DE60019134T2/de not_active Expired - Lifetime
2001
- 2001-02-12 TW TW090103013A patent/TWI262085B/zh not_active IP Right Cessation
2002
- 2002-02-27 NO NO20020983A patent/NO329773B1/no not_active IP Right Cessation
- 2002-03-01 US US10/086,973 patent/US7320963B2/en not_active Expired - Fee Related
2007
- 2007-11-26 US US11/986,829 patent/US7709457B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP4995388B2 (ja)	2012-08-08
ATE292187T1 (de)	2005-04-15
NO20020983L (no)	2002-04-24
US20020146830A1 (en)	2002-10-10
AU781684B2 (en)	2005-06-09
AUPQ259399A0 (en)	1999-09-23
CA2384425A1 (en)	2001-03-08
US20090054364A1 (en)	2009-02-26
AU7327500A (en)	2001-03-26
JP2003508456A (ja)	2003-03-04
EP1208218A2 (en)	2002-05-29
NO329773B1 (no)	2010-12-13
US7709457B2 (en)	2010-05-04
CA2384425C (en)	2011-01-25
TWI262085B (en)	2006-09-21
EP1208218B1 (en)	2005-03-30
DE60019134D1 (de)	2005-05-04
DE60019134T2 (de)	2006-02-09
WO2001015755A3 (en)	2002-02-28
ES2240157T3 (es)	2005-10-16
US7320963B2 (en)	2008-01-22
WO2001015755A2 (en)	2001-03-08

Publication	Publication Date	Title
NO20020983D0 (no)	2002-02-27	Metoder og blandinger til administrasjon av terapeutiske midler
Li et al.	2019	Charge-convertible polymers for improved tumor targeting and enhanced therapy
Dai et al.	2021	Red blood cell membrane-camouflaged nanoparticles loaded with AIEgen and Poly (I: C) for enhanced tumoral photodynamic-immunotherapy
Lei et al.	2020	Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation
Nuhn et al.	2016	pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation
Furgeson et al.	2003	Modified linear polyethylenimine− cholesterol conjugates for DNA complexation
Cheng et al.	2024	Injectable hydrogels as emerging drug-delivery platforms for tumor therapy
Jindal et al.	2021	Nanomaterials-mediated immunomodulation for cancer therapeutics
Zhang et al.	2016	Folate-conjugated polyspermine for lung cancer–targeted gene therapy
Li et al.	2021	Single micelle vectors based on lipid/block copolymer compositions as mRNA formulations for efficient cancer immunogene therapy
Gao et al.	2024	Injectable and photocurable gene scaffold facilitates efficient repair of spinal cord injury
Wang et al.	2020	Designed DNA nanostructure grafted with erlotinib for non-small-cell lung cancer therapy
Fewell et al.	2009	Treatment of disseminated ovarian cancer using nonviral interleukin‐12 gene therapy delivered intraperitoneally
Song et al.	2024	Design and evaluation of synthetic delivery formulations for peptide-based cancer vaccines
Kim et al.	2024	Injectable hydrogel systems for local cancer therapy
Zhang et al.	2023	Tumor-associated macrophages regulating a polymer nanoplatform for synergistic treatment of breast tumors
Chen et al.	2021	Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination
Diaz-Dussan et al.	2020	Oncogenic epidermal growth factor receptor silencing in cervical carcinoma mediated by dynamic sugar-benzoxaborole polyplexes
Wang et al.	2023	Iontophoresis‐Driven Microneedle Arrays Delivering Transgenic Outer Membrane Vesicles in Program that Stimulates Transcutaneous Vaccination for Cancer Immunotherapy
Li et al.	2024	Potential applications of ROS-responsive silk fibroin materials in smart drug delivery systems
Wang et al.	2025	A Metal–Organic Framework-Based Immune-Regulating Nanocarrier Depot for Enhanced Combination Cancer Immunotherapy
Gu et al.	2024	Molecule engineering strategy of toll-like receptor 7/8 agonists designed for potentiating immune stimuli activation
Guo et al.	2025	Engineering of sono-activatable immunogels for immunometabolism disorder normalization therapy of breast cancer
Zhang et al.	2025	Enhancing immunotherapy using a synergistic T-lymphocyte and neutrophil-targeting activation (TNTa) strategy for triple-negative breast cancer treatment
Karnaki et al.	2024	Thermoresponsive hydrogels: current status and future perspectives

Legal Events

Date	Code	Title	Description
2017-04-24	MM1K	Lapsed by not paying the annual fees